TrialJournal for immunotherapy of cancer2026

Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.

Jin Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.